Johnson & Johnson
says it is cooperating with the federal government having received a subpoena seeking documents related to the sales and marketing of its anemia drug Procrit.
The company made the announcement Friday after the markets had closed. However, J&J provided no details on the subpoena that was issued by the inspector general of the Department of Health and Human Services.
Procrit, which is sold under the name Eprex in some markets, produced $1.85 billion in sales for the first half of this year.
The company's sales and marketing practices for Procrit and five other drugs are also being examined by New York attorney general Eliot Spitzer. Previously, J&J said it had received a letter request from Spitzer's office on July 27 seeking documents pertaining to marketing, sales and clinical trials. J&J said it is responding to the request.
For the second quarter, J&J earned $2.46 billion, or 82 cents a share, on revenue of $11.49 billion. Third-quarter financial results are scheduled to be released Oct. 12.